A Spanish biomedical research networking center has developed an innovative biosensor for the detection and/or diagnosis of Staphylococcus aureus (S. aureus) with a high level of sensitivity and selectivity. They are looking to establish license, research cooperation or joint venture agreements.
This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions like universities, hospitals, and technological centers distributed around the country.
Throughout history, the Staphylococcus aureus (S. aureus) has been one of the human pathogens of greatest clinical significance. Currently, according to data from the National Nosocomial Infection Surveillance System (NNISS) of the Center for Disease Control (CDC), the S. aureus is the main microorganism responsible for nosocomial infections in Intensive Care Units (ICUs), such as primary bacteremia, pneumonia associated with mechanical ventilation or surgical wound infection.In the community, S. aureus causes a significant number of infections of variable severity, with greater frequency of skin and soft tissue, but it is also responsible for infections of greater severity and with great socioeconomic impact, such as osteoarticular infections and endocarditis, among others.
One of the main drawbacks associated with the detection of S. aureus is the correct identification and differentiation using current biochemical techniques, which also require a lot of time, and specialized personnel and equipment. It is very likely that in recent years there has been a multitude of cases in which S. aureus infections have been underdiagnosed or not correctly identified, making it difficult or even impossible for the patient to recover. Developing a new efficient, fast, and reliable diagnostic method is therefore essential.
The present invention describes a biosensor for the detection and / or diagnosis of Staphylococcus aureus that solves the problems of the devices and methods of the state of the art. This innovative technology allows fast and easy detection of the pathogen with a high level of sensitivity and selectivity. Based on this biosensor, a detection method and a method of diagnosing diseases caused by said pathogenic bacteria have also been developed.
Potential industrial partners, either Biotech or Medtech, are sought in order to enter into R&D collaboration (further development of the medical device) until clinical proof-of-concept and ultimately the commercialization of the product (license agreement); or research organization for further development of the device, in order to collaborate in innovation projects (clinical proof-of-concept). Besides, an investor for financial support for setting-up of a spin-off company is sought under a joint venture agreement.